Thompson MA, Henderson JP, Shah PK, et al. - Use of convalescent plasma to treat patients with hematologic cancers and COVID-19 was associated with a potential survival benefit.

• This cohort study included 966 hospitalized patients with hematologic cancer and COVID-19.

• Comparison was performed between 143 convalescent plasma recipients and 823 untreated control patients.

• Improved 30-day mortality [HR (hazard ratio), 0.60] in relation to convalescent plasma treatment was observed post-adjustment for potential confounding factors.

• This link continued to be significant after propensity score matching (HR, 0.52).

• Among 338 patients admitted to ICU, significantly lower mortality was noted in convalescent plasma recipients vs nonrecipients.

• Among 227 cases needing mechanical ventilatory support, significantly lower mortality was seen in those who received convalescent plasma vs nonrecipients.